Citations

Clear

1526 citation(s) found for "Sun, Yu".

A Coronavirus Disease 2019 Pandemic Pivot: Development of the American Board of Anesthesiology’s Virtual APPLIED Examination
Keegan, Mark T. , McLoughlin, Thomas M, Fiadjoe, John E. , Pisacano, Margaret M., Harman, Ann E., Patterson, Andrew J., Warner, David O. , Sun, Huaping

Mayo Clinic

Anesthesia & Analgesia | October 21, 2021 | Volume: 133 | Issue: 5 | Pages: 1331-1341

10.1213/ane.0000000000005750 | PMID 34517394 Get It

In 2020, the coronavirus disease 2019 (COVID-19) pandemic interrupted the administration of the APPLIED Examination, the final part of the American Board of Anesthesiology (ABA) staged examination system for initial certification. In response, the ABA developed, piloted, and implemented an Internet-based “virtual” form of the examination to allow administration of both components of the APPLIED Exam (Standardized Oral Examination and Objective Structured Clinical Examination) when it was impractical and unsafe for candidates and examiners to travel and have in-person interactions. This article describes the development of the ABA virtual APPLIED Examination, including its rationale, examination format, technology infrastructure, candidate communication, and examiner training. Although the logistics are formidable, we report a methodology for successfully introducing a large-scale, high-stakes, 2-element, remote examination that replicates previously validated assessments.
Corrigendum to ‘Induction of Wnt signaling antagonists and p21-activated kinase enhances cardiomyocyte proliferation during zebrafish heart regeneration’
Peng, Xiangwen , Lai, Kaa Seng, She, Peilu , Wang, Tingting , Zhou, Yating , Sun, Jianjian , Jin, Da‐Qing , Liao, Lujian , Liu, Jiandong , Zhong, Tao P. , Kang, Junsu , Li, Guobao, Jin, Daqing, Xu, Xiaolei , Lee, Ethan N. , Poss, Kenneth D.

Mayo Clinic

Journal of Molecular Cell Biology | October 20, 2021 | Volume: 13 | Issue: 12 | Pages: 921-921

10.1093/jmcb/mjab064 | PMID 35092682 Get It

Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease
Domenighetti, Cloé , Sreelatha, Ashwin Ashok Kumar , Grover, Sandeep , Mohamed, Océane, Portugal, Berta , May, Patrick , Bobbili, Dheeraj Reddy , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew , Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Kawamura, Yusuke , Hattori, Nobutaka , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P. van de, Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Hellberg, Clara , Clarke, Carl E , Morrison, Karen , Krainc, Dimitri , Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Elbaz, Alexis , Deutschländer, Angela B., Puschmann, Andreas , Bardien, Soraya , Bobbili, Dheeraj R , Toft, Mathias , Ezquerra, Mario , Elbaz, Alexis , Grover, Sandeep , May, Patrick , Ferreira, Joaquim J , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Sugier, Pierre‐Emmanuel , Schulte, Claudia , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Gagliardi, Monica , Matsuo, Hirotaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Guedes, Leonor Correia , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Tan, Manuela , Farrer, Matthew J. , Domenighetti, Cloé

Mayo Clinic

Journal of Parkinson's Disease | October 9, 2021 | Volume: 12 | Issue: 1 | Pages: 267-282

10.3233/jpd-212851 | PMID 34633332 Get It

Background: Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson’s disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation. Objective: To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases. Methods: We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017). Results: We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60–0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking. Conclusion: Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.
P077 Reliability of the Clinical Characterization of Isolated REM Sleep Behavior Disorder
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Guevarra, C, Timm, Paul, Angel, E, Mazeika, Gandis, Shprecher, David , Angel, Elise, Louis, Erik K. St.

Mayo Clinic

SLEEP Advances | October 7, 2021 | Volume: 2 | Issue: Supplement_1 | Pages: A46-A46

10.1093/sleepadvances/zpab014.121 Get It

Abstract Purpose Compare agreements between polysomnography-based (PSG) diagnosis of isolated REM-sleep-behavior-disorder (iRBD) and Non-REM-Hypertonia (NRH), a novel biomarker independently associated with synucleinopathy-related neurodegenerative diseases. Methods Sixteen patients with histories of dream-enactment-behavior (DEB)(women=38%; age:64.6±13.0) underwent PSG with simultaneously-recorded Sleep Profiler (SP). Two boarded sleep neurologists independently characterized iRBD. Physician1 combined abnormal qualitative REM-sleep-without-atonia (RSWA) by submental electromyography, with video-confirmation of probably DEB. Physician2 relied solely on qualitative RSWA. SP was auto-staged, technically reviewed, and reprocessed for automated abnormal NRH detection. Kappa scores measured physician and NRH agreements. Results In the 14 records with REM sleep, iRBD was characterized in: Physician1=64%, Physician2=79%, NRH=71% of the records. Across the three methods, unanimous iRBD agreement occurred in 57% of the records (positive=7, negative=1). The between-physician agreement in iRBD classifications was fair (kappa=0.32). The agreement between NRH and Physician1 was moderate (kappa=0.52) versus slight with Physician2 (kappa=0.05). NRH comparisons to consensus physician agreement yielded one false-positive and one false-negative iRBD finding. Physician2 classified: a) iRBD in two cases that were negative by Physician1 and NRH, and b) one negative case that Physician1 and NRH characterized as iRBD. Physician1 identified one negative case that was classified iRBD by Physician2 and NRH. Additionally, NRH was abnormal in one of the two records with no REM sleep. Discussion NRH may assist in iRBD risk assessment, given it agreed with at least one physician in 86% of the cases and the between-physician iRBD agreement was only fair. NRH also characterized iRBD-risk in patients with insufficient REM sleep for RSWA assessment.
P076 Sleep Staging Agreement Between Polysomnography and Sleep Profiler in Isolated REM Sleep Behavior Disorder
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Guevarra, C, Timm, Paul, Angel, E, Mazeika, Gandis, Shprecher, David , Angel, Elise, Louis, Erik K. St.

Mayo Clinic

SLEEP Advances | October 7, 2021 | Volume: 2 | Issue: Supplement_1 | Pages: A45-A46

10.1093/sleepadvances/zpab014.120 Get It

Abstract Purpose Evaluate the sleep staging agreement between polysomnography (PSG) and Sleep Profiler (SP) in patients with suspected isolated REM-sleep-behavior-disorder. Methods Twenty-six patients with reported dream-enactment-behavior (Site1=16, Site2=10; 27% women; age 64±13 years) underwent a diagnostic PSG with simultaneously recorded SP. A registered sleep-technologist at each site performed PSG-staging, while SP was auto-staged and technically reviewed/edited. Across technicians, the initial staging was blinded. Site1 then performed unblinded restaging of PSG=N3(N2) vs. SP=N2(N3) epochs, while Site2 conducted a blinded, carefully-targeted restaging of N3. Statistics included Cohen’s kappa and Chi-square analyses. Results Agreement between SP and Site1 vs. Site2 were significantly different for Wake (kappa:Site1=0.816;Site2=0.650;combined=0.736), stage N1 (kappa:Site1=0.149;Site2=0.228;combined=0.188), stage N2 (kappa:Site1=0.632;Site2=0.718;combined=0.659), stage N3 (kappa:Site1=0.715;Site2=0.368;combined=0.525) and REM (kappa:Site1=0.827;Site2=0.719;combined=0.766)(all P<0.001). After restaging of N3, the kappa values improved at Site1 (unblinded:N2=0.659/N3=0.883) and Site2 (blinded:N2=0.775/N3=0.736)(combined:N2=0.735/N3=0.851). The proportion of PSG-epochs restaged from N3 to N2 was 17% at Sites1 and 38% at Site2 (P<0.001), while Site1 had fewer remaining PSG=N3 vs. SP=N2 conflicts (5.6% vs. 20.8%, P<0.001). Compared to Site2, Site1 had a superior: REM kappa due to fewer SP=N2 disagreements (8.5% vs. 16.8%, P<0.001), and Wake kappa resulting from fewer SP=N1 (6.6 vs. 15.6%, P<0.001) and SP=N2 conflicts (5.9 vs. 12.0%, P<0.001). Conversely, the Site1 N1 kappa was inferior due to greater SP=wake disagreement (41.6% vs. 19.8%, P<0.001). Discussion N3 was excessively stage by both PSG technicians before restaging. At Site1, Wake, N3, and REM had almost-perfect-agreement with SP, while N2 had substantial-agreement. At Site2 and across-site, substantial-agreement was observed for Wake, N2, N3, and REM.
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis
Berti, Alvise , Hillion, Sophie , Hummel, Amber M., Son, Young Min , Chriti, Nedra, Peikert, Tobias, Carmona, Eva M. , Abdulahad, Wayel H. , Heeringa, Peter , Harris, Kristina M. , Clair, E. William St. , Brunetta, Paul , Langford, Carol A. , Kallenberg, Cees G. M., Stone, John H. , Grandi, Guido , Cornec, Divi, Carmona, Eva M , Berti, Alvise , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Sun, Jie , Pers, Jacques-Olivier , Specks, Ulrich , Cornec, Divi

Mayo Clinic

JCI Insight | October 7, 2021 | Volume: 6 | Issue: 22 | Pages: No page available

10.1172/jci.insight.150999 | PMID 34618687 Get It

BACKGROUND Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody–associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3–reactive (PR3 + ) B cells. METHODS Multicolor flow cytometry in combination with bioinformatics and functional in vitro studies were performed on baseline samples of PBMCs from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-AAV and myeloperoxidase-AAV (MPO-AAV) and 27 healthy controls (HCs). Clinical data and outcomes from the trial were correlated with PR3 + B cells (total and subsets). RESULTS The frequency of PR3 + B cells among circulating B cells was higher in participants with PR3-AAV (4.77% median [IQR, 3.98%–6.01%]) than in participants with MPO-AAV (3.16% median [IQR, 2.51%–5.22%]) and participants with AAV compared with HCs (1.67% median [IQR, 1.27%–2.16%], P < 0.001 for all comparisons), implying a defective central tolerance checkpoint in patients with AAV. Only PBMCs from participants with PR3-AAV contained PR3 + B cells capable of secreting PR3-ANCA IgG in vitro, proving they were functionally distinct from those of participants with MPO-AAV and HCs. Unsupervised clustering identified subtle subsets of atypical autoreactive PR3 + memory B cells accumulating through the maturation process in patients with PR3-AAV. PR3 + B cells were enriched in the memory B cell compartment of participants with PR3-AAV and were associated with higher serum CXCL13 levels, suggesting an increased germinal center activity. PR3 + B cells correlated with systemic inflammation (C-reactive protein and erythrocyte sedimentation rate, P < 0.05) and complete remission ( P < 0.001). CONCLUSION This study suggests the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients with PR3-AAV, elucidating the selection process of autoreactive B cells. Trial registration ClinicalTrials.gov NCT00104299. Funding The Vasculitis Foundation, the National Institute of Allergy and Infectious Diseases of the NIH, and the Mayo Foundation for Education and Research.
GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer
Burleson, Marieke , Deng, Janice , Qin, Tai, Duong, Thu Minh, Yan, Yuqian , Gu, Xiang , Das, Debodipta , Easley, Acarizia, Liss, Michael A. , Yew, P. Renée , Bedolla, Roble, Kumar, Addanki P. , Huang, Tim H.‐M. , Zou, Yi , Chen, Chun‐Liang , Sun, Lu‐Zhe , Boyer, Thomas , Chen, Yidong , Chen, Chun-Liang , Huang, Rui , Sun, Lu-Zhe , Chen, Yidong , Huang, Haojie

Mayo Clinic

Molecular Cancer Research | October 5, 2021 | Volume: 20 | Issue: 1 | Pages: 62-76

10.1158/1541-7786.mcr-21-0108 | PMID 34610962 Get It

Abstract Although the Sonic hedgehog (SHH) signaling pathway has been implicated in promoting malignant phenotypes of prostate cancer, details on how it is activated and exerts its oncogenic role during prostate cancer development and progression is less clear. Here, we show that GLI3, a key SHH pathway effector, is transcriptionally upregulated during androgen deprivation and posttranslationally stabilized in prostate cancer cells by mutation of speckle-type POZ protein (SPOP). GLI3 is a substrate of SPOP-mediated proteasomal degradation in prostate cancer cells and prostate cancer driver mutations in SPOP abrogate GLI3 degradation. Functionally, GLI3 is necessary and sufficient for the growth and migration of androgen receptor (AR)–positive prostate cancer cells, particularly under androgen-depleted conditions. Importantly, we demonstrate that GLI3 physically interacts and functionally cooperates with AR to enrich an AR-dependent gene expression program leading to castration-resistant growth of xenografted prostate tumors. Finally, we identify an AR/GLI3 coregulated gene signature that is highly correlated with castration-resistant metastatic prostate cancer and predictive of disease recurrence. Together, these findings reveal that hyperactivated GLI3 promotes castration-resistant growth of prostate cancer and provide a rationale for therapeutic targeting of GLI3 in patients with castration-resistant prostate cancer (CRPC). Implications: We describe two clinically relevant mechanisms leading to hyperactivated GLI3 signaling and enhanced AR/GLI3 cross-talk, suggesting that GLI3-specific inhibitors might prove effective to block prostate cancer development or delay CRPC.
Fully automated quantification of cardiac chamber and function assessment in 2-D Echocardiography: clinical feasibility of deep learning-based algorithms
Kim, Sekeun , Jeon, Jaeik, Park, Hyung‐Bok , Jeon, Jaeik , Arsanjani, Reza , Heo, Ran , Lee, Sang‐Eun , Moon, Inki , Yoo, Sun Kook , Chang, Hyuk‐Jae

Mayo Clinic

No container title available | September 30, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-945163/v1 Get It

Abstract Objectives: We aimed to compare the segmentation performance of the current prominent deep learning (DL) algorithms with ground-truth segmentations and to validate the reproducibility of the manually created 2D echocardiographic four cardiac chamber ground-truth annotation.Background: Recently emerged DL based fully-automated chamber segmentation and function assessment methods have shown great potential for future application in aiding image acquisition, quantification, and suggestion for diagnosis. However, the performance of current DL algorithms have not previously been compared with each other. In addition, the reproducibility of ground-truth annotations which are the basis of these algorithms have not yet been fully validated.Methods: We retrospectively enrolled 500 consecutive patients who underwent transthoracic echocardiogram (TTE) from December 2019 to December 2020. Simple U-net, Res-U-net, and Dense-U-net algorithms were compared for the segmentation performances and clinical indices such as left atrial volume (LAV), left ventricular end diastolic volume (LVEDV), LV end systolic volume (LVESV), LV mass, and ejection fraction (EF) were evaluated. The inter- and intra- observer variability analysis was performed by two expert sonographers for a randomly selected echocardiographic view in 100 patients (apical 2-chamber, apical 4-chamber, and parasternal short axis views).Results: The overall performance of all DL methods was excellent (average Dice similarity coefficient (DSC) 0.91 to 0.95 and average Intersection over union (IOU) 0.83 to 0.90), with the exception of LV wall area on PSAX view (average DSC of 0.83, IOU 0.72). In addition, there were no significant difference in clinical indices between ground truth and automated DL measurements. For inter- and intra observer variability analysis, the overall intra observer reproducibility was excellent: LAV (ICC = 0.995), LVEDV (ICC = 0.996), LVESV (ICC = 0.997), LV mass (ICC = 0.991) and EF (ICC = 0.984). The inter-observer reproducibility was slightly lower as compared to intraobserver agreement: LAV (ICC = 0.976), LVEDV (ICC = 0.982), LVESV (ICC =0.970), LV mass (ICC = 0.971), and EF (ICC = 0.899).Conclusions: The three current prominent DL-based fully automated methods are able to reliably perform four-chamber segmentation and quantification of clinical indices. Furthermore, we were able to validate the four cardiac chamber ground-truth annotation and demonstrate an overall excellent reproducibility, but still with some degree of inter-observer variability.
Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis
Chen, Yue , Cheng, Xingyu , Sun, Chenyu , Kim, Na Hyun , Kailas, Sujatha, Qureshi, Faisal, Karadsheh, Zeid, Wu, Yile , Hu, Lei , Zhou, Zhen , Bhan, Chandur , Kim, Keun Young , Manem, Raveena, Cheng, Ce , Zhou, Qin , Sun, Chenyu

Mayo Clinic

Postgraduate Medical Journal | September 30, 2021 | Volume: 98 | Issue: 1165 | Pages: 866-870

10.1136/postgradmedj-2021-140432 | PMID 37063031 Get It

AbstractObjectivesStudies on the association between metformin use and the risk of oesophageal cancer (OC) have generated controversial findings. This updated meta-analysis was conducted to reassess the effects of metformin on OC.MethodsA comprehensive search strategy was conducted to select relevant studies from origination to February 2021. Heterogeneity was evaluated through the Q test and I2 statistics. HRs and 95% CIs were pooled through either random-effect or fixed-effect models. Meta-regression, subgroup analyses, sensitivity analysis and publication bias diagnosis were also performed.ResultsSeven studies with 5 426 343 subjects were included. Metformin use was associated with reduced risk of OC (HR=0.69, 95% CI 0.54 to 0.87, p&lt;0.001). Sensitivity analysis suggested that the results were relatively stable.ConclusionMetformin is associated with a reduced risk of OC. More well-designed studies are still needed to further elaborate on these associations.PROSPERO registration numberCRD42021237127.